«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2025 05

Page:

857-862

Research Field:

Publishing date:

Info

Title:

Research progress on predictive biomarkers related to the efficacy of radiotherapy and chemotherapy in head and neck squamous cell carcinoma

Author(s):

ZHANG Bingyi¹; SUN Daqing²; HAO Furong²; LI Jianwen²

1.School of Clinical Medicine,Shandong Second Medical University,Shandong Weifang 261000,China;2.Department of Oncology Radiotherapy,Weifang People's Hospital,Shandong Weifang 261000,China.

Keywords:

head and neck squamous cell carcinoma; radiation therapy; chemotherapy; predictive biomarkers; mismatch repair deficiency; PD-L1

PACS:

R739.91

DOI:

10.3969/j.issn.1672-4992.2025.05.021

Abstract:

Surgery is considered the standard treatment for head and neck squamous cell carcinoma (HNSCC),but locally advanced patients cannot be cured by complete resection through surgery,and surgery combined with simultaneous radiotherapy is the standard treatment for such patients.However,traditional treatments such as surgery and radiotherapy can cause head and neck organ damage to a certain extent,thus affecting the quality of life of patients.In recent years,we have actively sought predictive biomarkers related to radiotherapy efficacy,such as HPV,p16,PD-L1,PD-L2,interferon-¦Ã,and tumor mutation load,to improve efficacy while reducing the adverse effects of radiotherapy.In this paper,we describe the predictive value of mismatch repair deficiency (dMMR) and PD-L1 for the efficacy of radiotherapy in locally advanced head and neck squamous carcinoma.

References:

£Û1£ÝLIU W,PANG Y,YU X,et al.Pan-cancer analysis of NUDT21 and its effect on the proliferation of human head and neck squamous cell carcinoma£ÛJ£Ý.Aging (Albany NY),2024£¬16(4):3363-3385.
£Û2£ÝMACHIELS JP,REN¦I LEEMANS C,GOLUSINSKI W,et al.Squamous cell carcinoma of the oral cavity,larynx,oropharynx and hypopharynx:EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis,treatment and follow-up£ÛJ£Ý.Ann Oncol,2020,31(11):1462-1475.
£Û3£ÝJOHNSON DE,BURTNESS B,LEEMANS CR,et al.Head and neck squamous cell carcinoma £ÛJ£Ý.Nat Rev Dis Primers,2020,6(1):92.
£Û4£ÝGUO Y,NAKASHIMA T,CHO BC,et al.Clinical decision pathway and management of locally advanced head and neck squamous cell carcinoma:A multidisciplinary consensus in Asia-Pacific£ÛJ£Ý.Oral Oncol,2024,148:106657.
£Û5£ÝGUPTA T,KANNAN S,GHOSH-LASKAR S,et al.Concurrent chemoradiotherapy with cisplatin given once-a-week versus every-three weekly in head and neck squamous cell carcinoma:Non-inferior,equivalent,or superior£ÛJ£Ý.Oral Oncol,2022,134:106130.
£Û6£ÝKUMAI T,KOMATSUDA H,WAKISAKA R,et al.Concurrent chemoradiotherapy with cisplatin and docetaxel for head and neck squamous cell carcinoma£ÛJ£Ý.Clin Otolaryngol,2022,47(1):228-233.
£Û7£ÝXU AA,MIAO JJ,WANG L,et al.Efficacy of concurrent chemoradiotherapy alone for loco-regionally advanced nasopharyngeal carcinoma:long-term follow-up analysis£ÛJ£Ý.Radiat Oncol,2023,18(1):63.
£Û8£ÝÎÀÑÇéª,³ÂêØ.¾Ö²¿ÍíÆÚÍ·¾±²¿ÁÛ״ϸ°û°©µÄ»¯ÁƼ°°ÐÏò½øÕ¹£ÛJ£Ý.ɽ¶«´óѧ¶ú±ÇºíÑÛѧ±¨,2021,35(03):118-124. WEI Yanan,CHEN Xi.Chemotherapy and targeted progression of locally advanced head and neck squamous cell carcinoma£ÛJ£Ý.Journal of Otolaryngology and Ophthalmology of Shandong University,2021,35(03):118-124.
£Û9£ÝÀî·¼,ÖìÔ¾ºì.Í·¾±²¿ÁÛ°©µÄ×ÛºÏÖÎÁƽøÕ¹£ÛJ£Ý.Ö×Áöҩѧ,2016,6(01):4-10. LI Fang,ZHU Yuehong.Advances in comprehensive treatment of head and neck squamous cell carcinoma£ÛJ£Ý.Oncology Pharmacy,2016,6(01):4-10.
£Û10£ÝCAUDELL JJ,TORRES-ROCA JF,GILLIES RJ,et al.The future of personalised radiotherapy for head and neck cancer£ÛJ£Ý.Lancet Oncol,2017,18(5):266-273.
£Û11£ÝPARMAR K,MOHAMED A,VAISH E,et al.Immunotherapy in head and neck squamous cell carcinoma:An updated review£ÛJ£Ý.Cancer Treat Res Commun,2022,33:100649.
£Û12£ÝPANDRUVADA S,KESSLER R,THAI A.Head and neck cancer treatment in the era of molecular medicine£ÛJ£Ý.Adv Cancer Res,2023,160:205-252.
£Û13£ÝDESHMUKH AV,GUPTA A,CHAUDHARI AG,et al.Correlation of p53 expression with clinical presentation and prognosis of oral squamous cell carcinoma patients:A pilot study£ÛJ£Ý.Indian J Otolaryngol Head Neck Surg,2022,74(Suppl 2):1836-1840.
£Û14£ÝGU Z,YAO Y,YANG G,et al.Pharmacogenomic landscape of head and neck squamous cell carcinoma informs precision oncology therapy£ÛJ£Ý.Sci Transl Med,2022,14(661):eabo5987.
£Û15£ÝBARROW E,HILL J,EVANS DG.Cancer risk in Lynch Syndrome£ÛJ£Ý.Fam Cancer,2013,12(2):229-240.
£Û16£ÝSENGHORE T,WANG WC,CHIEN HT,et al.Polymorphisms of mismatch repair pathway genes predict clinical outcomes in oral squamous cell carcinoma patients receiving adjuvant concurrent chemoradiotherapy£ÛJ£Ý.Cancers (Basel),2019,11(5):598.
£Û17£ÝBROOKSBANK K,MARTIN SA.DNA mismatch repair deficient cancer-Emerging biomarkers of resistance to immune checkpoint inhibition£ÛJ£Ý.Int J Biochem Cell Biol,2023,164:106477.
£Û18£ÝHE Y,ZHANG L,ZHOU R,et al.The role of DNA mismatch repair in immunotherapy of human cancer£ÛJ£Ý.Int J Biol Sci,2022,18(7):2821-2832.
£Û19£ÝMESTRALLET G,BROWN M,BOZKUS CC,et al.Immune escape and resistance to immunotherapy in mismatch repair deficient tumors£ÛJ£Ý.Front Immunol,2023,14:1210164.
£Û20£ÝHAUSE RJ,PRITCHARD CC,SHENDURE J,et al.Classification and characterization of microsatellite instability across 18 cancer types £ÛJ£Ý.Nat Med,2016,22(11):1342-1350.
£Û21£ÝCORTES-CIRIANO I,LEE S,PARK WY,et al.A molecular portrait of microsatellite instability across multiple cancers£ÛJ£Ý.Nat Commun,2017,8:15180.
£Û22£ÝCHALLONER BR,WOOLSTON A,LAU D,et al.Genetic and immune landscape evolution in MMR-deficient colorectal cancer£ÛJ£Ý.J Pathol,2024,262(2):226-239.
£Û23£ÝTAIEB J,SVRCEK M,COHEN R,et al.Deficient mismatch repair/microsatellite unstable colorectal cancer:Diagnosis,prognosis and treatment£ÛJ£Ý.Eur J Cancer,2022,175:136-157.
£Û24£ÝSTEMMER A,MARGALIT O,SERPAS V,et al.Immunotherapy in mismatch repair-deficient metastatic colorectal cancer-Outcome and novel predictive markers£ÛJ£Ý.Eur J Cancer,2024,198:113495.
£Û25£ÝOLAVE MC,GRAHAM RP.Mismatch repair deficiency:The what,how and why it is important£ÛJ£Ý.Genes Chromosomes Cancer,2022,61(6):314-321.
£Û26£ÝCOHEN R,TAIEB J,FISKUM J,et al.Microsatellite instability in patients with stage III colon cancer receiving fluoropyrimidine with or without oxaliplatin:An ACCENT pooled analysis of 12 adjuvant trials£ÛJ£Ý.J Clin Oncol,2021,39(6):642-651.
£Û27£ÝADDANTE F,D'AMATI A,SANTORO A,et al.Mismatch repair deficiency as a predictive and prognostic biomarker in endometrial cancer:A review on immunohistochemistry staining patterns and clinical implications£ÛJ£Ý.Int J Mol Sci,2024,25(2):1056.
£Û28£ÝGLAIRE MA,RYAN NA,IJSSELSTEIJN ME,et al.Discordant prognosis of mismatch repair deficiency in colorectal and endometrial cancer reflects variation in antitumour immune response and immune escape£ÛJ£Ý.J Pathol,2022,257(3):340-351.
£Û29£ÝHOREWEG N,NOUT RA,J¦aRGENLIEMK-SCHULZ IM,et al.Molecular classification predicts response to radiotherapy in the randomized PORTEC-1 and PORTEC-2 trials for early-stage endometrioid endometrial cancer£ÛJ£Ý.J Clin Oncol,2023,41(27):4369-4380.
£Û30£ÝZHAO L,LIAO X,HONG G,et al.Mismatch repair status and high expression of PD-L1 in nasopharyngeal carcinoma£ÛJ£Ý.Cancer Manag Res,2019,11:1631-1640.
£Û31£ÝCHANG AMV,CHIOSEA SI,ALTMAN A,et al.Programmed death-ligand 1 expression,microsatellite instability,Epstein-Barr virus,and human papillomavirus in nasopharyngeal carcinomas of patients from the philippines£ÛJ£Ý.Head Neck Pathol,2017,11(2):203-211.
£Û32£ÝCHEN FM,ZHANG YX,LI XF,et al.The prognostic value of deficient mismatch repair in stage II-IVa nasopharyngeal carcinoma in the era of IMRT£ÛJ£Ý.Sci Rep,2020,10(1):9690.
£Û33£ÝCUI JW,LI Y,YANG Y,et al.Tumor immunotherapy resistance:Revealing the mechanism of PD-1/PD-L1-mediated tumor immune escape£ÛJ£Ý.Biomed Pharmacother,2024,171:116203.
£Û34£ÝWU M,HUANG Q,XIE Y,et al.Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation£ÛJ£Ý.J Hematol Oncol,2022,15(1):24.
£Û35£ÝZDRENKA M,KOWALEWSKI A,AHMADI N,et al.Refining PD-1/PD-L1 assessment forbiomarker-guided immunotherapy:A review£ÛJ£Ý.Biomol Biomed,2024,24(1):14-29.
£Û36£ÝGOLDSTRAW P,CHANSKY K,CROWLEY J,et al.The IASLC lung cancer staging project:Proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer£ÛJ£Ý.J Thorac Oncol,2016,11(1):39-51.
£Û37£ÝMATHIOS D,KIM JE,MANGRAVITI A,et al.Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM£ÛJ£Ý.Sci Transl Med,2016,8(370):370ra180.
£Û38£ÝJANJIGIAN YY,KAWAZOE A,YA¦rEZ P,et al.The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer£ÛJ£Ý.Nature,2021,600(7890):727-730.
£Û39£ÝVANNESTE BGL,VAN LIMBERGEN EJ,DUBOIS L,et al.Immunotherapy as sensitizer for local radiotherapy£ÛJ£Ý.Oncoimmunology,2020,9(1):1832760.
£Û40£ÝLEE VH,LO AW,LEUNG CY,et al.Correlation of PD-L1 expression of tumor cells with survival outcomes after radical intensity-modulated radiation therapy for non-metastatic nasopharyngeal carcinoma£ÛJ£Ý.PLoS One,2016,11(6):e0157969.
£Û41£ÝSHI L,YANG Y,LI M,et al.LncRNA IFITM4P promotes immune escape by up-regulating PD-L1 via dual mechanism in oral carcinogenesis£ÛJ£Ý.Mol Ther,2022,30(4):1564-1577.
£Û42£ÝDONG Y,WANG Z,MAO F,et al.PD-1 blockade prevents the progression of oral carcinogenesis£ÛJ£Ý.Carcinogenesis,2021,42(6):891-902.
£Û43£ÝFU ZM,ZHANG DJ,GUO YY,et al.Expression of PD-L1 and CD4+ tumor-infiltrating lymphocytes predict survival in head and neck squamous cell carcinoma£ÛJ£Ý.Mol Clin Oncol,2022,16(3):59.
£Û44£ÝGIROLAMI I,MARLETTA S,FIORENTINO V,et al.Effect of radio-chemotherapy on PD-L1 immunohistochemical expression in head and neck squamous cell carcinoma£ÛJ£Ý.J Pers Med,2023,13(2):363.
£Û45£ÝMAO L,ZHOU JJ,XIAO Y,et al.Immunogenic hypofractionated radiotherapy sensitising head and neck squamous cell carcinoma to anti-PD-L1 therapy in MDSC-dependent manner£ÛJ£Ý.Br J Cancer,2023,128(11):2126-2139.
£Û46£Ý SEIWERT TY,BURTNESS B,MEHRA R,et al.Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012):an open-label,multicentre, phase 1b trial£ÛJ£Ý.Lancet Oncol,2016,17(7):956-965.
£Û47£ÝFERRIS RL,BLUMENSCHEIN GJR,FAYETTE J,et al.Nivolumab for recurrent squamous-cell carcinoma of the head and neck£ÛJ£Ý.N Engl J Med,2016,375(19):1856-1867.
£Û48£ÝFIEDLER M,WEBER F,HAUTMANN MG,et al.Biological predictors of radiosensitivity in head and neck squamous cell carcinoma£ÛJ£Ý.Clin Oral Investig,2018,22(1):189-200.

Memo

Memo:

ɽ¶«Ê¡Ò½Ò©ÎÀÉú¿Æ¼¼·¢Õ¹¼Æ»®ÏîÄ¿£¨±àºÅ£º202109030776£©

Common functions

Last Update: 1900-01-01